Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volasertib with induction chemotherapy in untreated AML
NCT02527174Phase 1Withdrawn
- Sponsor
- University of Alberta
- Start
- Nov 2016
- Primary completion
- May 2018
- Countries
- 1
01
Overview
Phase 1, open-label trial of volasertib in acute myeloid leukemia (AML), sponsored by University of Alberta. Primary endpoint: Toxicity profile at 35 days. Planned start Nov 2016; status: withdrawn.
02
Drugs
volasertib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02527174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02527174.